PURPOSE: The UDP glucuronosyltransferase 1A6 (UGT1A6) and cytochrome P450 2C9 (CYP2C9) enzymes participate in the metabolism of nonsteroidal anti-inflammatory drugs, endogenous substances, and carcinogens. Functional polymorphisms of UGT1A6 (T181A and R184S) and CYP2C9 (R144C and I359L) have been reported to modify the protective effect of aspirin on colorectal adenoma risk. We aimed to further investigate the effect of these genetic variants on the development of colorectal neoplasia. EXPERIMENTAL DESIGN: We examined the relationship between UGT1A6 and CYP2C9 genotype and colorectal adenoma recurrence in 546 patients participating in a randomized placebo-controlled aspirin intervention trial. RESULTS: Although colorectal adenoma recurrence was not significantly influenced by CYP2C9 genotype, carriers of variant UGT1A6 alleles were at significantly reduced risk of colorectal neoplasia recurrence [relative risk (RR), 0.68; 95% confidence interval (95% CI), 0.52-0.89]. This risk reduction was also evident when the analysis was confined to advanced neoplasia recurrence (RR, 0.71; 95% CI, 0.47-1.09). When patients were stratified by genotype and aspirin intervention, those with variant UGT1A6 alleles were at reduced recurrence risk irrespective of whether they received aspirin or placebo (RR, 0.62; 95% CI, 0.42-0.92 and RR, 0.63; 95% CI, 0.44-0.91, respectively). CONCLUSIONS: These findings confirm that UGT1A6 variants influence colorectal carcinogenesis independent of aspirin intake and suggest that they may have clinical value in secondary prevention programs for patients diagnosed with colorectal adenoma.
RCT Entities:
PURPOSE: The UDP glucuronosyltransferase 1A6 (UGT1A6) and cytochrome P450 2C9 (CYP2C9) enzymes participate in the metabolism of nonsteroidal anti-inflammatory drugs, endogenous substances, and carcinogens. Functional polymorphisms of UGT1A6 (T181A and R184S) and CYP2C9 (R144C and I359L) have been reported to modify the protective effect of aspirin on colorectal adenoma risk. We aimed to further investigate the effect of these genetic variants on the development of colorectal neoplasia. EXPERIMENTAL DESIGN: We examined the relationship between UGT1A6 and CYP2C9 genotype and colorectal adenoma recurrence in 546 patients participating in a randomized placebo-controlled aspirin intervention trial. RESULTS: Although colorectal adenoma recurrence was not significantly influenced by CYP2C9 genotype, carriers of variant UGT1A6 alleles were at significantly reduced risk of colorectal neoplasia recurrence [relative risk (RR), 0.68; 95% confidence interval (95% CI), 0.52-0.89]. This risk reduction was also evident when the analysis was confined to advanced neoplasia recurrence (RR, 0.71; 95% CI, 0.47-1.09). When patients were stratified by genotype and aspirin intervention, those with variant UGT1A6 alleles were at reduced recurrence risk irrespective of whether they received aspirin or placebo (RR, 0.62; 95% CI, 0.42-0.92 and RR, 0.63; 95% CI, 0.44-0.91, respectively). CONCLUSIONS: These findings confirm that UGT1A6 variants influence colorectal carcinogenesis independent of aspirin intake and suggest that they may have clinical value in secondary prevention programs for patients diagnosed with colorectal adenoma.
Authors: Elizabeth M Poole; Jeannette Bigler; John Whitton; Justin G Sibert; John D Potter; Cornelia M Ulrich Journal: Pharmacogenet Genomics Date: 2009-02 Impact factor: 2.089
Authors: Elizabeth L Barry; Elizabeth M Poole; John A Baron; Karen W Makar; Leila A Mott; Robert S Sandler; Dennis J Ahnen; Robert S Bresalier; Gail E McKeown-Eyssen; Cornelia M Ulrich Journal: Cancer Causes Control Date: 2012-10-19 Impact factor: 2.506
Authors: Beatriz Carvalho; Anke H Sillars-Hardebol; Cindy Postma; Sandra Mongera; Jochim Terhaar Sive Droste; Askar Obulkasim; Mark van de Wiel; Wim van Criekinge; Bauke Ylstra; Remond J A Fijneman; Gerrit A Meijer Journal: Cell Oncol (Dordr) Date: 2012-01-26 Impact factor: 6.730
Authors: Sushma S Thomas; Karen W Makar; Lin Li; Yingye Zheng; Peiying Yang; Lisa Levy; Rebecca Yvonne Rudolph; Paul D Lampe; Min Yan; Sanford D Markowitz; Jeannette Bigler; Johanna W Lampe; John D Potter Journal: BMC Med Genet Date: 2015-03-24 Impact factor: 2.103
Authors: José M Ladero; José A G Agúndez; Carmen Martínez; Gemma Amo; Pedro Ayuso; Elena García-Martín Journal: Front Genet Date: 2012-12-03 Impact factor: 4.599